HY-133 is under clinical development by HyPharm and currently in Phase I for Staphylococcal Infections. According to GlobalData, Phase I drugs for Staphylococcal Infections have a 63% phase transition ...

P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, Indiana 47405, United States ...